ZX-29 NEW
| Price | $93 | $243 | $383 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ZX-29 | CAS No.: 2254805-62-2 |
| Purity: 98.32% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ZX-29 |
| Description | ZX-29 is a potent and selective inhibitor of ALK with IC50 values of 2.1 nM, 1.3 nM, and 3.9 nM for ALK, ALK [L1196M], and ALK [G1202R] mutations, respectively. It also induces protective autophagy and exhibits antitumor effects. |
| In vitro | ZX-29 dose-dependently inhibits colony formation of NCI-H2228 cells. With an increase in ZX-29 concentration, the cell density decreased gradually, and the cells lost their normal morphology and become sharp and slender. In NCI-H2228 cells, ZX-29 (10 nM; 0-48 hours) inhibits the proliferation of and arrests the cells in G1 phase. ZX-29 (0-81 nM; 24-72 hours) treatment resulted in a decrease in the viability with time and dose. ZX-29 (10 nM; 24 hours) treatment causes typical signs of autophagy and the formation of autophagosomes and enhances the expression level of LC3 and Beclin1. ZX-29 (20 nM; 0-48 hours) treatment significantly increases the mRNA level of CHOP[1]. |
| In vivo | In a mouse xenograft model, ZX-29 treatment suppresses tumor growth[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 42.5 mg/mL (82.04 mM) |
| Keywords | arrest | antitumor | ZX29 | Resistance | ZX-29 | Anaplastic lymphoma kinase | Bcl-2 | Apoptosis | Inhibitor | CD246 | p-Akt | caspase-3 | endoplasmic | inhibit | CHOP | Anaplastic lymphoma kinase (ALK) | ALK tyrosine kinase receptor | ERS | Cluster of differentiation 246 | Autophagy | reticulum | p-STAT3 | ZX 29 |
| Inhibitors Related | Alectinib hydrochloride | Lorlatinib | SB-431542 | DMH-1 | RepSox | Crizotinib | Vactosertib | Ceritinib | LDN-193189 2HCl | Brigatinib | A 83-01 | ALK-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1Box |
VIP1Y
|
American HealthyMorph LLC
|
2025-01-08 | |
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1BOX |
VIP1Y
|
Shandong Huizhihan Supply Chain Co., Ltd
|
2024-11-05 | |
| $93.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY